Trump’s Latest Stock Portfolio: 10 Stocks to Buy
President Donald Trump’s stock trades have set off a frenzy of disclosures this year, and they are gaining attention in the debate over what a president should be allowed to own.
Zoetis Inc. (ZTS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 56,344 | $3,934,502 | +3% | 0.08% |
| 2. | Ranmore Fund Management Sean Peche | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $75.39 | 6,650 | $501,343.50 | 21,458 | 2026-05-13 | Filing | |
| $75.88 | 2,000 | $151,750.00 | 27,862 | 2026-05-13 | Filing | |
| $77.76 | 3,000 | $233,273.40 | 24,524 | 2026-05-11 | Filing | |
| $165.48 | 2,100 | $347,508.00 | 7,590 | 2021-02-19 | Filing | |
| $164.89 | 2,900 | $478,181.00 | 5,490 | 2021-02-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $127.55 | 10,800 | $1,377,531.36 | 101,337 | 2026-02-17 | Filing | |
| $126.46 | 9,200 | $1,163,432.92 | 112,137 | 2026-02-17 | Filing | |
| $170.00 | 652 | $110,840.00 | 15,129 | 2025-06-03 | Filing | |
| $170.00 | 326 | $55,420.00 | 15,781 | 2025-03-10 | Filing | |
| $166.14 | 1,210 | $201,029.40 | 11,245 | 2025-03-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,864,087 | $130,169,165 | 2.18% | |
| 2. | 1,785,312 | $124,668,337 | 0.86% | |
| 3. | 1,580,996 | $110,400,985 | 2.35% | |
| 4. | 819,278 | $57,210,182 | 0.99% | |
| 5. | 454,608 | $31,745,277 | 4.12% |
News See All
Zoetis’ Valuation Has Fallen Sharply, but Has the Market Overreacted?
The investment case for Zoetis Inc. (NYSE:ZTS) has changed significantly since declining demand in its U.S.
Zoetis (ZTS) Hit by Guidance Cuts, Met with Market Shrug
Middle Coast Investing, an investment advisor firm, released its second-quarter 2026 investor letter. The letter can be downloaded here.
Zoetis (ZTS) Has a Huge Animal Health Moat. Is It Starting to Crack?
Zoetis Inc. (NYSE:ZTS) has built one of the strongest franchises in animal health.
Zoetis (ZTS) Shares Drop After Earnings Revision
Impax Asset Management, based in London and specializing in sustainable investing, released its Q2 2026 investor letter for the “Impax US Sustainable Economy Fund”.
Zoetis Wins Emergency Authorization for Simparica Trio, Can It Support a Slowing U.S. Business?
The timing of Zoetis Inc.’s (NYSE:ZTS) latest regulatory win is particularly relevant for shareholders. Just one week after the animal-health company reported a 7% decline in U.S.
Zoetis Earnings Reveal a Divided Business, But Can its Pipeline Restore Growth?
Zoetis Inc. (NYSE:ZTS) entered 2026 as a leader in animal health, but its latest earnings show that even a strong market position cannot fully insulate the company from weaker consumer demand.
Michael Burry is Bullish on This Beaten-Down Healthcare Stock. Time to Buy?
Zoetis (NYSE:ZTS) is an animal health company. Michael Burry is long the stock, several media outlets reported, citing his Substack disclosures. The stock is down about 40% so far this year.
Zoetis (ZTS) Remains a Leader, So Why Was It Sold?
Polen Capital Management Llc released its “Polen Focus Growth Strategy” Q2 2026 investor letter. A copy of the letter can be downloaded here.
Zoetis (ZTS) Looked Like a Winner. What Went Wrong?
Brown Advisory, an investment management company, released its “Brown Advisory Global Leaders Strategy” for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here.
Hedge Fund Resource Center